Solana Company reports developments as a Nasdaq-listed company with a digital asset treasury dedicated to acquiring and holding Solana tokens (SOL) and a legacy neurotechnology medical-device business. News commonly covers SOL accumulation, staking rewards, NAV-per-share capital strategy, ATM and registered-direct equity financing, share repurchases, and financial results shaped by digital-asset fair value changes.
Company updates also describe institutional Solana infrastructure initiatives in Asia-Pacific, including validator and staking infrastructure, qualified-custody borrowing against natively staked SOL, and ecosystem partnerships with organizations such as Jito Foundation, Anchorage Digital, and Kamino.
Helius Medical Technologies (NASDAQ: HSDT) has submitted a request to the FDA for de novo classification and clearance of its Portable Neuromodulation Stimulator (PoNS) device, aimed at treating gait deficits in Multiple Sclerosis patients. The device was granted Breakthrough Designation on May 7, 2020. Preliminary Q2 2020 revenue is expected to be $0.1 million, down from $0.5 million in Q2 2019, while operating loss is projected at $3.7 million, an improvement from $5.8 million year-over-year. Cash reserves stand at $5.3 million as of June 30, 2020.
Helius Medical Technologies (Nasdaq: HSDT) announced its participation in the Virtual Summer Summit, scheduled from June 9th-12th, 2020. Management will present on June 9th at 4:30 p.m. ET. A live audio webcast will be available on the company's investor relations website, with an archived replay after the conference.
Helius focuses on neurological wellness, developing non-invasive technologies. Its first product, the Portable Neuromodulation Stimulator (PoNS™), targets gait deficits from neurological conditions.
Helius Medical Technologies (NASDAQ: HSDT) announced Breakthrough Designation for its PoNS™ device, aimed at treating gait deficits in Multiple Sclerosis patients. This designation allows expedited development and assessment by the FDA, with the goal of improving patient mobility through a non-drug treatment approach. The PoNS device is currently authorized in Canada and under investigation in the U.S. and other regions. The Breakthrough Devices Program facilitates timely access for critical medical devices while ensuring compliance with regulatory standards.
Helius Medical Technologies (HSDT) reported Q1 2020 financial results revealing a revenue decline to $0.2 million from $0.7 million in Q1 2019, driven primarily by decreased product sales of $191 thousand. The company experienced an operating loss of $4.0 million, a 41% improvement from the previous year. Net loss was $4.8 million, compared to a net income of $1.3 million in Q1 2019. Cash reserves decreased to $4.4 million as of March 31, 2020. Due to uncertainties from the COVID-19 pandemic, the full-year outlook has been withdrawn.
Summary not available.
Summary not available.